Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of high-dose atorvastatin on the cardiovascular risk associated with individual components of metabolic syndrome: a subanalysis of the Treating to New Targets (TNT) study.
Deedwania PC, Shepherd J, Breazna A, DeMicco DA; Treating to New Targets (TNT) Steering Committee Investigators. Deedwania PC, et al. Among authors: breazna a. Diabetes Obes Metab. 2016 Jan;18(1):56-63. doi: 10.1111/dom.12581. Diabetes Obes Metab. 2016. PMID: 26434404 Clinical Trial.
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study.
Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Waters DD, et al. Among authors: breazna a. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17. J Am Coll Cardiol. 2006. PMID: 17084252 Free article. Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; Treating to New Targets Investigators. Shepherd J, et al. Among authors: breazna a. Clin J Am Soc Nephrol. 2007 Nov;2(6):1131-9. doi: 10.2215/CJN.04371206. Epub 2007 Oct 17. Clin J Am Soc Nephrol. 2007. PMID: 17942759 Clinical Trial.
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Shepherd J, et al. Among authors: breazna a. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072. J Am Coll Cardiol. 2008. PMID: 18402899 Free article. Clinical Trial.
The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study.
Kostis JB, Breazna A, Deedwania PC, LaRosa JC; Treating to New Targets Steering Committee and Investigators. Kostis JB, et al. Among authors: breazna a. J Clin Hypertens (Greenwich). 2008 May;10(5):367-76. doi: 10.1111/j.1751-7176.2008.07851.x. J Clin Hypertens (Greenwich). 2008. PMID: 18453796 Free PMC article. Clinical Trial.
Comparison of effectiveness of atorvastatin 10 mg versus 80 mg in reducing major cardiovascular events and repeat revascularization in patients with previous percutaneous coronary intervention (post hoc analysis of the Treating to New Targets [TNT] Study).
Johnson C, Waters DD, DeMicco DA, Breazna A, Bittner V, Greten H, Grundy SM, LaRosa JC. Johnson C, et al. Among authors: breazna a. Am J Cardiol. 2008 Nov 15;102(10):1312-7. doi: 10.1016/j.amjcard.2008.07.023. Epub 2008 Sep 5. Am J Cardiol. 2008. PMID: 18993147 Clinical Trial.
45 results